Evidence map›Paper›PMID 15673726›Full record

ArticleAntimicrobial agents and chemotherapy2005

Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.

Po-Ren Hsueh, Yeu-Jun Lau, Yin-Ching Chuang, Jen-Hsien Wan, Wen-Kuei Huang, Jainn-Ming Shyr, Jing-Jou Yan, Kwok-Woon Yu, Jiunn-Jong Wu, Wen-Chien Ko and 5 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026
    Review
  2. InFuture microbiology · 2025
    Article
  3. In Silico Structural Modeling and Analysis of Interactions ofInternational journal of molecular sciences · 2021
    Article
  4. Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2018
    Review
  5. Review
  6. Triazole Resistance in Aspergillus spp.: A Worldwide Problem?Journal of fungi (Basel, Switzerland) · 2016
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Culture-positive invasive aspergillosis in a medical center in Taiwan, 2000-2009.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Efflux-mediated antifungal drug resistance.Clinical microbiology reviews · 2009
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Po-Ren HsuehDepartment of Laboratory Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Rd., Taipei 100, Taiwan. hsporen@ha.mc.ntu.edu.tw
Yeu-Jun Lau
Yin-Ching Chuang
Jen-Hsien Wan
Wen-Kuei Huang
Jainn-Ming Shyr
Jing-Jou Yan
Kwok-Woon Yu
Jiunn-Jong Wu
Wen-Chien Ko
Yi-Chueh Yang
Yung-Ching Liu
Lee-Jene Teng
Cheng-Yi Liu
Kwen-Tay Luh

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C. glabrata and C. krusei were susceptible to fluconazole. Among the 59 C. glabrata isolates, 16 (27%) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1%) C. glabrata isolates, voriconazole MICs were 2 to 4 microg/ml, and for all other Candida species isolates, voriconazole MICs were </=0.5 microg/ml. The proportions of isolates for which amphotericin B MICs were >/=2 microg/ml were 100% (3 isolates) for C. krusei, 11% (23 of 207 isolates) for Candida albicans, 3.0% (2 of 67 isolates) for Candida tropicalis, 20% (12 of 59 isolates) for C. glabrata, and 0% for both Candida parapsilosis and Candida lusitaniae. For three (4%) Cryptococcus neoformans isolates, fluconazole MICs were >/=16 microg/ml, and two (3%) isolates were not inhibited by 1 mug of amphotericin B/ml. For four (4.2%) of the Aspergillus isolates, itraconazole MICs were 8 microg/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50% (1 microg/ml) and 90% (2 microg/ml) nsrsid417869\delrsid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by </=1 microg of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.

Indexed as

Drug Resistance, FungalAntifungal AgentsAspergillosisAspergillusAzolesCandidaCandidiasisCryptococcosisCryptococcus neoformansDose-Response Relationship, DrugHumansMicrobial Sensitivity TestsPopulation SurveillanceTaiwanAntifungal AgentsAzoles

Identifiers

PMID15673726
PMCPMC547329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.